Theratechnologies, a Canada-based biopharma, is to be acquired by CB Biotechnology, an affiliate of Future Pak, a ...

Chinese biotech Brii Biosciences (HKEX: 2137) has licensed its experimental antibiotic BRII-693 to domestic pharma business ...

Spanish gene therapy specialist VIVEbiotech has named Patricio Massera as its new president, bringing in a seasoned CDMO ...

Pharmaceutical companies are heading toward a steep patent cliff that could strip more than $230 billion in US drug sales ...

Indian biosimilars developer Biocon Biologics, a subsidiary of Biocon Ltd has announced that the European Commission (EC) has ...

US pharma major Eli Lilly today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase III clinical trials ...

A new company is responsible for Japanese promotional activities for Actair, Stallergenes Greer’s sublingual immunotherapy ...

British drugmaker AstraZeneca (LSE: AZN) has gained European approval for Imfinzi (durvalumab) in combination with ...

UK pharma major AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal ...

Multinational pharmaceutical companies (MNCs) are facing significant challenges in China's vaccine market, as regulatory ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Anktiva (nogapendekin alfa inbakicept) for adults with BCG-unresponsive non-muscle invasive bladder cancer, where ...

In the high-stakes world of drug development, a pill is never just a pill. Every oral drug that reaches the market has passed through a tightly managed series of steps—none more critical, or more ...